CD274 and non-small cell lung carcinoma: Several studies of anti-PD-1/L1 therapeutic antibodies in multiple tumor types, including melanoma and NSCLC, have suggested that PD-L1 expression is associated with a greater likelihood of benefit [8, 32, 38–40].